UCL Institute of Neurology



Regional brain shrinkage in MS predicts disability

A research team led by UCL Institute of Neurology has identified the pattern of brain tissue loss in multiple sclerosis, enabling improved prediction of disability progression.

The study, published in Annals of Neurology, was one of the largest brain imaging studies ever conducted investigating multiple sclerosis (MS).

Publication date:

Professor Barkhof awarded 2018 John Dystel Prize

We are delighted to announce that Professor Frederik Barkhof, Professor of Neuroradiology at the UCL Institute of Neurology, has been awarded the 2018 John Dystel Prize for his outstanding contribution to multiple sclerosis research in the understanding, treatment and prevention of multiple sclerosis.

Publication date:

Cannabis-mimicking MS drug trial starts

A trial has started of a treatment that mimics the properties of cannabis to help reduce spasticity associated with multiple sclerosis (MS). The trial is being led by Dr Rachel Farrell, a consultant at the National Hospital for Neurology and Neurosurgery (UCLH) and Honorary Senior Lecturer at the UCL Institute of Neurology.

Publication date:

GABA neurotransmitter may be progressive MS marker

A neurotransmitter widely distributed in the brain may be a marker of a progressive multiple sclerosis, according to research led by Professor Olga Ciccarelli, UCL Institute of Neurology, published in Brain.

Publication date:

Acute optic neuritis: a review and proposed protocol

Optic neuritis is an inflammatory optic neuropathy that is frequently- but not always - associated with multiple sclerosis (MS). Despite recent developments in laboratory, imaging and electrophysiological techniques, no consensus guidelines have yet been formulated for the diagnostic work-up in patients presenting with optic neuritis.

Publication date:

Statins could help control MS

Research published in the Lancet, led by Dr Jeremy Chataway (Honorary Senior Lecturer, UCL Institute of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery), has found that a high dose of the cholesterol-lowering drug simvastatin reduces the rate of brain shrinkage in people with secondary progressive multiple sclerosis (SPMS) by about 40% (the untreated rate is approximately 0.6% a year).

Publication date:

Imaging the evolution of multiple sclerosis

Congratulations to Professor David Miller (Department of Neuroinflammation) who was the 2011 Raymond D Adams Memorial Lecturer at the Department of Neurology, Massachusetts General Hospital, Boston. He delivered this highly prestigious lecture, entitled “Imaging the evolution of multiple sclerosis”, on December 8th.  

Publication date:

Roads closed for powerful MRI scanner delivery

Roads were closed in central London on Saturday as a new high-powered, six tonne MRI scanner was installed at the UCL Institute of Neurology in Queen Square.

Publication date: